Going with the gut: probiotics as a novel therapy for hepatocellular carcinoma

Going with the gut: probiotics as a novel therapy for hepatocellular carcinoma

Alberto Nicoletti, Maurizio Pompili, Antonio Gasbarrini, Francesca R. Ponziani

Internal Medicine, Gastroenterology and Hepatology, Fondazione Policlinico A Gemelli IRCCS, Rome, Italy

Correspondence to: Francesca R. Ponziani, MD, PhD. Division of Internal Medicine, Gastroenterology and Hepatology, Fondazione Policlinico A Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy. Email: francesca.ponziani@gmail.com.

Comment on: Wan MLY, El-Nezami H. Targeting gut microbiota in hepatocellular carcinoma: probiotics as a novel therapy. Hepatobiliary Surg Nutr 2018;7:11-20.

Submitted Jan 13, 2019. Accepted for publication Jan 22, 2019.

doi: 10.21037/hbsn.2019.01.16

Hepatocellular carcinoma (HCC) is a leading cause of death worldwide (1). It is the most frequent primary liver tumor and usually occurs in patients affected by liver cirrhosis (1).

Nowadays, the main treatment options for HCC include surgical or locoregional approaches and systemic drugs, but despite the significant improvements in medical management the prognosis of patients with advanced HCC is still poor (1).

The term “gut microbiota” refers to the totality of microorganisms that are physiologically found in our intestinal tract. In normal conditions, it complements the biological functions of the host and contributes to the maintenance of the health and homeostasis of the whole organism.

The gut microbiota is a critical part of the gut-liver axis, which finely regulates the strict relationship between the liver and the intestine. A dysfunction of the gut barrier can occur either during a primary intestinal perturbation or secondary to liver disease, causing an increase in intestinal permeability (IP). Hence, bacterial products [e.g., lipopolysaccharide (LPS), bacterial DNA] are delivered in large, non-physiological amounts to the liver through the portal circulation (2). These pathogen-associated molecular patterns (PAMPs), interacting with the Toll-like receptors (TLRs), can trigger an inflammatory response causing detrimental effects on liver homeostasis. An imbalance in the composition and function of the gut microbiota (dysbiosis) associated with the increase in IP, which are both hallmarks of liver cirrhosis, further increase the flow of microbial toxins to the liver (3). The inability to provide a proper clearance of baneful substances and the occurrence of a secondary inflammatory response have been correlated with the progression of liver disease and the occurrence of liver cirrhosis complications (2).

As thoroughly reviewed by Wan and El-Nezami, the gut microbiota and the gut-liver axis derangement could also favor the occurrence of HCC via different mechanisms (4).

Indeed, LPS translocated from the intestinal lumen is able to activate the TLR4 on Kupffer cells, concurring to the development and the maintenance of an inflammatory, pro-oncogenic, environment. In confirmation of this, an overexpression of TLR4 in tumor tissue has been observed in HCC. Furthermore, as already demonstrated in other clinical settings, a chronic, non-resolving inflammation can “freeze” the immune system, blocking those mechanism that are critical to recognize and eliminate malignant cells, thus favoring tumor escape from the immune surveillance.

Recent studies identified a specific gut microbiota fingerprint that can be associated with the presence of early HCC, and it is now clear that bacterial metabolites such as deoxycholic acid (DCA) can favor hepatocarcinogenesis through the damage of hepatocellular DNA and liver inflammation (5-8). Finally, an increase in tissue T helper 17 (Th17) lymphocytes and the consequent overexpression of interleukin (IL) 17A correlates to inflammation, tumor angiogenesis and poor prognosis in patients with HCC (9). Interestingly, Th17 cells are mainly generated in the gut following the interaction of the immune system with the gut microbiota (10).

Therefore, the gut microbiota is involved in the process of hepatocarcinogenesis at different levels, mainly through persistent inflammation, toxic products and immune system dysregulation.

According to these evidences, Wan and El-Nezami elegantly hypothesized a consistent role for probiotics for the treatment of HCC (4).

Indeed, probiotics exert protective effects on the intestinal mucosa, influence the gut microbiota composition, regulate the metabolism of microorganism in order to disadvantage the production and release of toxins, metabolize harmful dietary compounds and modulate the immune response (11). They also reduce the release of LPS, inhibiting the proliferation of pathogenic Gram-negative bacteria (12). Another favorable effect of probiotics is the detoxification of carcinogens, such as aflatoxin B1. Several bacterial strains can bind mycotoxins and the administration of probiotics has been correlated with a decrease in urinary excretion of aflatoxin-DNA adduct, a biomarker of liver cancer risk (13). Bifidobacteria and Lactobacilli, that are commonly found in probiotics, can produce short chain fatty acids (SCFAs). These metabolites exert a trophic effect on the intestinal mucosa, strengthening the gut barrier. Importantly, they favor a decrease in the Th17 polarization and a reduction of inflammatory cytokines, that are relevant elements in the process of tumorigenesis (14). Interestingly, tumor hypoxia due to a decrease in angiogenesis and a shift to anaerobic metabolism has been reported after treatment with probiotics (14). Probiotics can induce an upregulation of the antitumor immune response further impairing the tumor growth both directly and by inhibiting the suppression of the immune system by tumor cells (15).

Altogether, these findings strengthen the hypothesis that the modulation of the gut microbiota can protect against the development and progression of HCC, but some considerations are required.

Most of these results derive from animal models. Therefore, human studies are necessary for translating these evidences into clinical practice. The design should be particularly accurate, especially with regard to some specific steps.

Firstly, a precise choice of the probiotic to be used is crucial, as the beneficial effects are often species- and/or strain specific (16). In this regard, since the process of hepatocarcinogenesis is complex and involves multiple mechanisms, a personalized approach to the modulation of the intestinal microbiota cannot disregard the identification of a dysbiotic signature unequivocally associated with HCC. Probably, in this scenario, the use of probiotic combinations could provide better results; conversely, in most studies, commercially available probiotics mixtures have been tested. Thus, further efforts are needed for the identification of bacterial strains that specifically contrast the pathogenic mechanisms of hepatocarcinogenesis. Indeed, the ideal probiotic should supply microorganisms needed for gut homeostasis, contrast harmful bacteria proliferation and metabolism, reinforce the gut barrier preventing bacterial translocation, limit the absorption of toxins, decrease intestinal inflammation and positively modulate the immune system.

Furthermore, it is not known to what extent the administration of probiotics may change the composition and function of the intestinal microbiota, and especially how long the effects may last over time. It should also be considered that the gastrointestinal tract also harbors fungi and viruses, whose communities are interconnected with bacteria and the host. Scarce data are available about the composition and function of this network, which could become a promising tool for a future gut-targeted therapeutic approach. At present, the safety of probiotics and the simplicity of administration make them ideal for modulating the microbiota compared to other types of therapeutic interventions.

In conclusion, the use of probiotics in association with other preemptive or therapeutic procedures for the modulation of the gut microbiota of patients with HCC is currently still a dream in the drawer. However, it is time to go with our gut and design randomized controlled trials in large populations of patients to confirm the proteiform beneficial effects postulated for probiotics in this clinical setting.




Conflicts of Interest: The authors have no conflicts of interest to declare.


  1. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018;69:182-236. [Crossref]
  2. Ponziani FR, Zocco MA, Cerrito L, et al. Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications. Expert Rev Gastroenterol Hepatol 2018;12:641-56. [Crossref] [PubMed]
  3. Ponziani FR, Gerardi V, Pecere S, et al. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications. World J Gastroenterol 2015;21:12322-33. [Crossref] [PubMed]
  4. Wan MLY, El-Nezami H. Targeting gut microbiota in hepatocellular carcinoma: probiotics as a novel therapy. Hepatobiliary Surg Nutr 2018;7:11-20. [Crossref] [PubMed]
  5. Eiró N, Altadill A, Juárez LM, et al. Toll-like receptors 3, 4 and 9 in hepatocellular carcinoma: Relationship with clinicopathological characteristics and prognosis. Hepatol Res 2014;44:769-78. [Crossref] [PubMed]
  6. Ponziani FR, Bhoori S, Castelli C, et al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease. Hepatology 2019;69:107-20. [Crossref] [PubMed]
  7. Yoshimoto S, Loo TM, Atarashi K, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013;499:97-101. [Crossref] [PubMed]
  8. Ren Z, Li A, Jiang J, et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut 2019;68:1014-23. [Crossref] [PubMed]
  9. Zhang JP, Yan J, Xu J, et al. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 2009;50:980-9. [Crossref] [PubMed]
  10. Ivanov II, Atarashi K, Manel N, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009;139:485-98. [Crossref] [PubMed]
  11. Kirpich IA, McClain CJ. Probiotics in the treatment of the liver diseases. J Am Coll Nutr 2012;31:14-23. [Crossref] [PubMed]
  12. Zhang HL, Yu LX, Yang W, et al. Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats. J Hepatol 2012;57:803-12. [Crossref] [PubMed]
  13. El-Nezami HS, Polychronaki NN, Ma J, et al. Probiotic supplementation reduces a biomarker for increased risk of liver cancer in young men from Southern China. Am J Clin Nutr 2006;83:1199-203. [Crossref] [PubMed]
  14. Li J, Sung CY, Lee N, et al. Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice. Proc Natl Acad Sci U S A 2016;113:E1306-15. [Crossref] [PubMed]
  15. Marinelli L. Tenore GCNovellino E. Probiotic species in the modulation of the anticancer immune response. Semin Cancer Biol 2017;46:182-90. [Crossref] [PubMed]
  16. Hill C, Guarner F, Reid G, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014;11:506-14. [Crossref] [PubMed]
Cite this article as: Nicoletti A, Pompili M, Gasbarrini A, Ponziani FR. Going with the gut: probiotics as a novel therapy for hepatocellular carcinoma. Hepatobiliary Surg Nutr 2019;8(3):295-297. doi: 10.21037/hbsn.2019.01.16